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Gene variants and expression 
changes of SIRT1 and SIRT6 
in peripheral blood are associated 
with Parkinson’s disease
Rita Maszlag‑Török1, Fanni A. Boros1, László Vécsei1,2 & Péter Klivényi1*
Parkinson’s disease (PD) is a neurodegenerative disease caused by complex interaction between 
genetic and environmental factors. There is a growing body of evidence of the involvement of 
sirtuins (SIRTs) in disease pathomechanism. SIRTs are NAD+‑dependent histone deacetylases which 
take part in various cellular functions. However, available data of the relationship between SIRT 
gene polymorphisms and PD is limited. Our aim was to investigate the possible association of 10 
SNPs identified within non‑mitochondrial SIRTs, SIRT1, -2 and -6 with the risk of PD in Hungarian 
population, and to compare the expression level of these SIRTs between healthy controls and PD 
patients. Our results showed that rs3740051 and rs3818292 of SIRT1 and rs350843, rs350844, 
rs107251, rs350845 and rs350846 of SIRT6 show weak association with PD risk. On the contrary 
rs12778366 and rs3758391 of SIRT1 and rs10410544 of SIRT2 did not show association with PD. 
Moreover, we detected that mRNA level of SIRT1 was down‑regulated, and mRNA level of SIRT6 
was up‑regulated, while SIRT2 mRNA level was not altered in the peripheral blood of PD patients 
as compared to controls. The difference in both cases was more pronounced when comparing the 
early‑onset PD group to the control cohort. Nevertheless, mRNA level changes did not show any 
association with the presence of any of the investigated SNPs either in the PD or in the control group. 
In conclusion, our findings suggest that non‑mitochondrial sirtuins, SIRT1 and ‑6 but not SIRT2 might 
contribute to the pathogenesis of PD in the Hungarian population both via their altered mRNA levels 
and via gene alterations identified as specific SNPs.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder  worldwide1. It is characterized 
by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, 
which are accumulations of aggregated alpha-synuclein (SNCA) in the cytoplasm of surviving neurons. Although 
the exact pathomechanism of PD is still not fully elucidated, several molecular mechanisms leading to neuronal 
death thus culminating in the development of the disease have been described. These include mitochondrial 
dysfunction, oxidative stress, microglia activation and neuroinflammation. Regarding aetiological background, 
the most accepted concept is that PD results from complex interactions among molecular changes related to 
aging, environmental factors and genetic  constitution2.
Sirtuins (SIRTs) are NAD+-dependent class III histone deacetylase enzymes which take part in various bio-
logical processes. There are seven SIRT homologs (SIRT1-7) showing different enzymatic specificity which are 
localized differently in mammalian cells. SIRT1, -6, and -7 reside primarily in the nucleus, SIRT2 is cytoplasmic, 
while SIRT3, -4 and -5 are predominantly localized in mitochondria. The pathways in which SIRTs are involved, 
such as stress response, mitochondrial dysfunction, oxidative stress, protein aggregation and inflammation, are 
closely linked to cell survival and are intertwined with age-related neurodegenerative  diseases3. Mitochondrial 
dysfunction in particular has been strongly implicated in the pathogenesis of the neurodegenerative  disorders4. 
Thus, it is not surprising that SIRTs, which affect mitochondrial function via the regulation of various metabolic 
processes, also affect diseases related to  neurodegeneration5. On the other hand a growing body of evidence 
implicates non-mitochondrial SIRTs—such as SIRT1, -2 and -6—as well in the development and course of 
OPEN
1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, 




Scientific Reports |        (2021) 11:10677  | https://doi.org/10.1038/s41598-021-90059-z
www.nature.com/scientificreports/
neurodegenerative diseases, including  PD6. Data obtained on the effect of these SIRTs on PD in models indicate 
diverse roles of these enzymes in disease development, however, results are sometimes contradictory (see below).
SIRT1 expression was found to be decreased in both toxin induced and genetically modified models of 
 PD7. Resveratrol, a SIRT1 activating compound was found to be neuroprotective in both 6-OHDA and MPTP 
models of PD, as treatment with the compound decreased dopaminergic neuron  death8–10. Moreover, SIRT1 
overexpression was found to inhibit the formation of alpha-synuclein aggregates via the activation of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and molecular chaperons in neuroblastoma 
cells and in a mice model of the disease,  respectively11.
Data on the role of SIRT2 in PD are contradictory: SIRT2 has been reported to exacerbate alpha-synuclein 
toxicity via deacetylation of alpha-synuclein12. On the other hand, SIRT2 knockout mice presented reduced 
MPTP-induced dopaminergic cell damage and inhibition of SIRT2 activity reduced alpha-synuclein toxicity thus 
had a protective effect on dopaminergic neurons in both in vitro and in vivo models of the  disease13,14. However, 
there are also data arguing against the protective effect of SIRT2 inhibition, as in diquat and rotenone treated 
cells enzymatic inhibition of SIRT2 enhanced the formation of alpha-synuclein aggregates resulting in increased 
cell death, while elevated SIRT2 expression had a cell protective  effect15.
Reports on the role of SIRT6 in age related diseases and neurodegeneration are similarly contradictious. 
Overexpression of SIRT6 was found to increase the lifespan of mice, and ameliorate certain age-associated 
disease (such as cancer) in  rodents16. On the contrary, regarding its neurodegeneration modulating properties, 
SIRT6 resembles SIRT2. SIRT6 knockout was found to be protective in a MPTP-induced mouse model of PD, 
while SIRT6 overexpressing mice showed more severe disease pathology, indicated by increased dopaminergic 
cell death compared to wild type  animals17.
Despite of the considerable amount of data from in vitro and in vivo models pointing to the role of SIRTs 
in PD, little is known about the involvement of these enzymes/genes in the disease from results obtained from 
studying patients in Caucasian population. Genetic variations of SIRT genes may affect the transcription regu-
lation of the gene, or the translation and/or enzymatic activity of the protein, and various SIRT gene variants 
have been identified to be associated with different  malignancies18,19. However, only limited data are available 
on the significance of SIRT alterations in PD, therefore studying SIRT expression and SIRT SNPs in relation to 
this disease is highly important.
Therefore, one of the aims of the current study was to compare the frequency of non-mitochondrial SIRT 
variants in Hungarian sporadic PD (SPD) patients and healthy control individuals. We selected SIRT SNPs that 
are intensively studied or have been identified recently as potential risk factors for PD. The frequencies of these 
polymorphisms vary greatly in different populations and to our knowledge their occurrence in relation to PD 
has not been investigated in the Central European population so far. Our study included four SIRT1 (rs3818292, 
rs3758391, rs12778366, rs3740051), one SIRT2 (rs10410544) and five SIRT6 (rs350843, rs350844, rs350845, 
rs350846 and rs107251) polymorphisms. Our further goal was to determine whether changes in the expression 
levels of SIRT1,-2 and -6 genes are observable between PD patients and controls, and in relation to the presence 
of these SIRT gene variants.
Earlier, the frequencies of a total of 41, SIRT1-6 genes SNPs were investigated in Spanish PD patients. No asso-
ciation was found between any of the polymorphisms and disease occurrence in the investigated  population20. 
More recently, a case–control study reported that a SNP (rs12778366) in the promoter region of SIRT1 and 
another (rs2015) in the 3′ UTR region of SIRT2 were associated with PD in Chinese Han population. Moreover, 
this study reported down-regulated SIRT1 expression, and up-regulated SIRT2 mRNA level in PD patients as 
compared to non-PD controls. These gene expression changes correlated with the presence of the rs12778366 
of SIRT1 and r2015 of SIRT2  variants21. Results of a meta-analysis by Nicholatos et al. suggested associations 
between the presence of six SIRT6 SNPs and the incidence of PD. All the six polymorphisms were also associated 
with elevated expression level of SIRT6 in the brain tissue (from frontal or mid-temporal cortex) of PD patients 
in American  population17. The findings outlined above strongly support the involvement of non-mitochondrial 
SIRTs (SIRT1, SIRT2 and SIRT6) in the pathogenesis of PD.
Results
Associations between SIRT SNPs and PD. The frequency of each polymorphism investigated in this 
study was in accord with Hardy–Weinberg Equilibrium (HWE) in the studied population groups. The genotype 
and allele frequencies of the investigated SNPs and their associations with the risk of PD are summarized in 
Table 1. We observed strong associations between PD and the minor allele frequencies of rs3740051 (p = 0.0212) 
and rs3818292 (p = 0.00978) variants of SIRT1, and rs350843 (p = 0.045), rs350846 (p = 0.025) of SIRT6. However, 
none of these associations were statistically significant after the FDR correction (p = 0.0832, p = 0.0832, 0.0880 
and p = 0.0832 respectively). SNPs rs3740051, rs3818292, rs350843, rs350844, rs107251, rs350845 and rs350846 
showed a trend of association in the dominant model, suggesting a possible link between these SNPs and the 
development of PD. The genotype and allele frequencies of the other investigated polymorphisms (rs12778366, 
rs3758391 of SIRT1 and rs10410544 of SIRT2) showed no significant differences between cases and controls. 
Allele and genotype distributions of the SIRT1 and SIRT2 SNPs were also similar after stratification by age, dis-
ease onset or gender. On the other hand, 5 SNPs (rs350843, rs350844, rs107251, rs350845 and rs350846) of the 
SIRT6 gene showed a significant association with EOPD (p = 0.025, p = 0.037, p = 0.037, p = 0.037, and p = 0.025). 
These significant differences however disappeared after FDR correction (p = 0.074, p = 0.074, 0.074, p = 0.074 and 
p = 0.074 respectively).
Haplotype analysis of the investigated SNPs revealed two haplotype blocks, one in both SIRT1 and SIRT6 
genes. Strong linkage disequilibrium (LD) was detected between rs3758391, rs3740051 and rs3818292 in SIRT1 
and rs350843, rs350844, rs107251, rs350845 and rs350846 in the SIRT6 gene (Fig. 1). In the haplotype-based 
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case–control analysis, the TGG haplotype in SIRT1and the AATAC haplotype in SIRT6 showed a trend of asso-
ciation with PD (p = 0.0767 in both cases). The frequencies of other haplotypes showed no significant differences 
between the two groups (Table 2). Comparison of subgroups (stratified by age at disease onset or gender) did 
not reveal significant differences in the haplotype frequencies.
Associations between PD and SIRT mRNA levels. In order to determine whether differences in the 
expression of SIRT genes are detectable when comparing PD and control samples, and whether the presence of 
any of the studied SNPs has an effect on the expression of the corresponding SIRT gene, we compared the levels 
of SIRT1, SIRT2 and SIRT6 mRNAs in peripheral blood samples of PD patients and healthy controls. We found 
that the level of SIRT1  mRNA was significantly reduced in PD patients compared to controls (fold change = 0.71, 
p = 0.0002). Moreover, SIRT1 expression was significantly down-regulated in the EOPD cohort as compared to 
Table 1.  Statistical results of the investigated SNP. OR odds ratio, CI confidence interval. Marginal associations 
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Figure 1.  Linkage disequilibrium (LD) plots of single nucleotide polymorphisms (SNPs) of SIRT1 (A) and SIR6 
(B) genes. Shading of diamonds and numbers represent LD between markers based on the D’ values.
4
Vol:.(1234567890)
Scientific Reports |        (2021) 11:10677  | https://doi.org/10.1038/s41598-021-90059-z
www.nature.com/scientificreports/
healthy controls (fold change = 0.66, p = 0.00018). There was no significant difference between EOPD and LOPD 
(fold change = 0.88 p = 0.105) or control and LOPD (fold change = 0.82 p = 0.105, Fig. 2) groups in the levels of 
SIRT1 mRNA.
On the contrary, SIRT6 mRNA levels of PD cases were significantly higher compared to healthy controls (fold 
change = 1.14, p = 0.0078). Furthermore, SIRT6 was significantly up-regulated in the EOPD group compared to 
controls (fold change = 1.17, p = 0.0078, Fig. 3). Comparison of EOPD and LOPD subgroups or control group and 
LOPD patients (fold change = 0.98, p = 0.554 and fold change = 1.1, p = 0.086, respectively) yielded no significant 
difference (Fig. 3).
Similarly, no significant difference was observed in SIRT2 mRNA levels between patient and control groups 
(fold change = 0.95, p = 0.102, Fig. 4).
Analysis of mRNA levels in relation to the presence of different alleles did not reveal any association either 
in the PD or in the control group.
Discussion
There is an increasing body of evidence showing that sirtuins are essential factors in delaying cellular senescence 
and extending lifespan by the regulation of various cellular processes. It was reported that overexpression of some 
sirtuins suppress cellular senescence via delaying the age-related telomere shortening and promoting DNA dam-
age repair mechanisms. These data suggest that due to their involvement in various signalling pathways sirtuins 
are critical modulators of aging thus play an important role in age-related diseases such as neurodegenerative 
 disorders22.
In recent years a growing body of evidence has accumulated on the importance of SIRTs in PD  pathogenesis6. 
SIRT1 and SIRT2 seem to have opposite effects on the development and course of the  disease21. A recent meta-
analysis revealed strong association between SIRT6 polymorphisms and PD, suggesting a pathogenic role of 
SIRT6 in the  disease17. However, apart from these reports, data regarding the role of the genetic variants of SIRTs 
in Caucasian populations are scarce.
By the present study, we aimed to assess the frequency of a total of 10 SNPs of SIRT1, -2 and -6 genes in 
Hungarian SPD patients and healthy controls. Furthermore, we aimed at determining if changes in the expres-
sion levels of SIRT1, -2 and -6 genes are observable between PD patients and controls and also in relation to the 
presence of the studied SIRT gene variants. All investigated SNPs are located in putative functional regions of 
the genes and/or have been reported to be associated with several diseases.
SIRT1 regulates numerous physiological processes and its involvement in the pathogenesis of various diseases 
is well  grounded23.
In the present work we identified a marginal association between the presence of two SIRT1 SNPs (rs3740051 
and rs3818292) and PD risk. The frequencies of minor (G) allele of both SNPs were higher in the control group, 
suggesting a protective effect against the development of the disease. In addition, we detected significant down-
regulation in SIRT1 mRNA level in blood samples of PD patients compared to controls. The difference was most 
prominent when comparing the EOPD group to the control cohort. It is well known that there are some genetic 
markers which consistently show association with age of onset in PD. Several mutations in parkin, PINK-1, 
leucine-rich repeat kinase 2 and glucocerebrosidase genes are associated with  EOPD24–29. These observations 
suggest that the underlying molecular mechanisms of EOPD differ from that of LOPD. However, it seems that 
the mutations of these genes alone may not be enough to differentiate EOPD from LOPD due to their differing 
prevalence in different populations. Our results suggest that changes in the expression of SIRT1 affect PD devel-
opment by influencing the time of disease onset. Thus variations in the level of SIRT1 mRNA in the periphery 
might serve as a potential biomarker for EOPD.
Recently, Chang et al. reported an association between the occurrence of PD and the rs12778366 SNP in Han 
Chinese population. Chang and colleagues proposed that rs12778366, which is localized in the promoter region 
of SIRT1, might influence the expression of the  gene21. Our results show no significant association between the 
rs12778366 SNP and PD, and we detected no effect of the minor allele on gene expression. This could partly 
be explained by the different allele distribution and contribution to the disease in different study populations.
SIRT2 is a key modulator of many cellular processes such as cell cycle, myelinisation, antioxidant mechanisms 
and  aging30. Therefore the role of SIRT2 in neurodegenerative diseases is an intensively studied area of research 
attracting increasing  interest31–35. Previous studies indicated that the presence of the T allele of the rs10410544 
Table 2.  Haplotype frequencies in PD cases and controls. Haplotype block 1 is identified by rs3758391–
rs3740051–rs3818292 in SIRT1 gene, and haplotype block 2 is identified by rs350843–rs350844–rs107251–
rs350845–rs350846 in SIRT6 gene.
Haplotype PD case (freq) Control (freq) Chi p-value Adjust p
SIRT1
CAA 0.720 0.709 0.107 0.744 0.743
TAA 0.246 0.209 1.339 0.247 0.309
TGG 0.034 0.070 4.667 0.0307 0.0767
SIRT6
CGCGG 0.856 0.903 3.709 0.0541 0.090
AATAC 0.136 0.082 5.161 0.0231 0.0767
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SIRT2 variant increased the risk of AD development in both Chinese and Caucasian  populations36,37. In 2017, 
Singh et al. reported that over-expression of SIRT2 in an in vitro model of the disease reduced the formation 
of alpha-synuclein aggregates. Furthermore, elevated SIRT2 protein activity was measured in the brain of AD 
and PD patients, suggesting a possible compensatory mechanism against neuronal stress and cell  death15. More 
recently elevated serum SIRT2 level was measured in PD patients relative to controls. The increase of SIRT2 level 
was found to significantly correlate with UPDRS and disease duration among patients with early-phase  PD38. 
In this study we investigated whether the AD susceptibility factor rs10410544 polymorphism exerts an effect on 
SIRT2 mRNA level in PD patients. Our results did not show any association between the presence of this SIRT2 
SNP and PD, and there was no significant difference detectable in the mRNA levels of patients’ and control 
groups. These data are in accord with results obtained from Spanish and Chinese populations, which showed no 
association between the presence of the minor allele of the rs10410544 SNP and  PD20,21. However, the expression 
level of SIRT2 was not investigated in the studies mentioned above. Recently a significant association was reported 
between the SIRT2 allele containing rs2015 polymorphism and PD risk in Chinese population. SIRT2 expression 
was found to be significantly increased among patients with TT genotype compared to those homozygous for 
the G allele, suggesting a disease modifying effect of the  polymorphism21. Based on previous findings of SIRT2 






















































































































Figure 2.  Expression level of SIRT1 in the peripheral blood of PD patients and healthy controls. Significant 
down-regulation of SIRT1 expression was measured in PD group compared to controls (A), and in EOPD 
patients compared to controls (B) as well. No significant difference was detected in the case of EOPD vs. 
LOPD (C) and LOPD vs. control group (D) comparisons. Fold changes are shown with standard deviation. PD 
Parkinson’s disease, Ctrl control, EOPD early onset Parkinson’s disease, LOPD late onset Parkinson’s disease, n.s. 
non-significant; ***p < 0.001 after FDR correction.
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over-expression inducing dopaminergic cell death while enzyme inhibition exerting neuroprotective effects, it 
was concluded that elevated SIRT2 levels contribute to higher PD risk. In contrast to previous studies reporting 
on SIRT2 effects on microtubule stability, formation of alpha-synuclein aggregation, neuroinflammation and 
 autophagy39 our results do not support the role of SIRT2 in PD.
SIRT6, similarly to other sirtuins, regulates different molecular functions related to DNA repair, tumorgen-
esis, neurodegeneration and  aging40. Recently Nicholatos et al. found that SIRT6 knock out cells were more 
resistant to  apoptosis17. This study also reported a significant increase in SIRT6 expression in PD patients’ brain. 
The meta-analysis of two GWA studies revealed six SIRT6 SNPs to be associated with increased SIRT6 mRNA 
levels and also with increased risk of  PD17. In line with previous findings of increased SIRT6 expression in post 
mortem PD brain samples, we detected elevated SIRT6 level in peripheral blood leukocytes of PD patients as 
compared to controls. Moreover, we found that 5 SNPs, which form a LD block in the N-terminus of the SIRT6 
gene, have a marginal PD risk increasing effect. The association between allele frequencies, mRNA level and 
PD was more pronounced in the EOPD group. These data emphasize the significance of SIRT6 in the disease, 
particularly in EOPD cases.






















































































































Figure 3.  SIRT6 expression levels in peripheral blood of PD patients and controls. SIRT6 expression was 
significantly increased in PD patients compared to controls (A). The up-regulation was more pronounced in 
EOPD group compared to controls (B). No significant difference was detected between EOPD vs. LOPD (C) 
and LOPD vs. control group (D). Fold changes are shown with standard deviation. PD Parkinson’s disease, 
Ctrl control, EOPD early onset Parkinson’s disease, LOPD late onset Parkinson’s disease, n.s. non-significant; 
**p < 0.01 after FDR correction.
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Though an intergroup difference in SIRT6 mRNA level was detected, the low number of samples belonging 
to particular genotypes prevented us from establishing associations between the different genotypes and mRNA 
levels. To our knowledge, this is the first report which compared the level of SIRT6 mRNA in easily accessible 
peripheral blood cells of PD patients and healthy controls. Elevation in SIRT6 expression in brain tissue of PD 
patients has been reported  recently17. Our finding that the change in SIRT6 level is detectable also in peripheral 
blood samples might open possibilities to find new potential markers of diagnostic tests for PD.
In conclusion, we analysed the presence of 10 SNPs of SIRT1, 2 and 6 genes in Hungarian PD patients for 
the first time. We observed association of two SIRT1 SNPs (rs3740051 and rs3818292) and five SIRT6 variants 
(rs350843, rs350844, rs107251, rs350845 and rs350846) with PD risk. Additionally, we detected down-regulated 
SIRT1 and up-regulated SIRT6 mRNA levels in peripheral blood of PD patients. Our results, in line with data of 
others’, strenghten the involvement of SIRTs in the pathogenesis of PD.
Whether the presence of the variants of these genes and their expression changes are in causal relationship 
with the disease, need further elucidation. Research focusing on this matter is highly warranted: considering the 
cellular functions SIRT1 and SIRT6 fulfill, gaining insight into their role in the disease can lead to a better under-
standing of the underlying pathomechanisms of PD and also help in the identification of new therapeutic targets.
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Figure 4.  Expression levels of SIRT2 in the peripheral blood of PD patients and healthy controls. The 
expression level did not shown differences between the investigated groups. Fold changes are shown with 
standard deviation. PD Parkinson’s disease, Ctrl control, EOPD early onset Parkinson’s disease, LOPD late onset 
Parkinson’s disease, n.s. non-significant.
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Material and methods
Subjects. Frequencies of SIRT gene variants were investigated in a cohort consisting of 177 SPD patients (age 
64.8 ± 9.9 years, male:female ratio 87:90) and a group of 171 healthy controls (age 62.9 ± 10.9 years, male:female 
ratio 76:95). For data analysis, the patient’s group was divided into two subgroups based on the appearance of the 
first symptoms: the early-onset (EOPD; disease onset ≤ 60 years) group comprised of 104, the late-onset (LOPD; 
disease onset > 60 years) group composed of 73 patients (Supplementary Table S1).
Samples of 84 PD patients (age 62.3 ± 9.8 years) and 52 healthy controls (age 60.3 ± 14.4 years) were involved 
from the above described groups for comparison of mRNA levels (Supplementary Table S2).
PD was diagnosed based on medical history and physical examination by movement disorder specialists. All 
those involved in the study were patients under the care of the Department of Neurology, University of Szeged. 
Patients with secondary parkinsonism were excluded. Individuals of the control group had no history of neuro-
logical or psychiatric disorders. All study participants were of Hungarian origin. The study protocol was approved 
by the Medical Research Council Scientific and Research Ethics Committee (47066-3/2013/EKU (556/2013)) 
and Ethics Committee of the Faculty of Medicine (22/2012), University of Szeged. All study participants gave 
written informed consent in accordance with the Helsinki Declaration.
Genotyping. Genomic DNA was extracted by a standard desalting  method41 from peripheral venous blood. 
The extracted DNA was stored at − 20 °C until further use. The analysis of SIRT gene variants was performed 
with TaqMan allelic discrimination assays obtained from Thermo Fisher Scientific (Thermo Scientific, Waltham, 
MA, USA).
RNA extraction and analysis. For RNA analysis 5 ml of venous blood was collected between 8 a.m. and 
11 a.m. Samples were treated with Trizol reagent (MRC Inc., Cincinnati, OH, USA) within 2 h of collection, and 
were kept on − 80 °C until further processing. Total RNA was isolated according to the manufacturer’s protocol 
(MRC Inc., Cincinnati, OH, USA). RNA concentrations were determined using MaestroNano spectrophotom-
eter (MaestroGenInc, Hsinchu, Taiwan). cDNA was synthesized from 1 μg total RNA with random hexamer 
primers using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). The mRNA 
levels of SIRT1, SIRT2 and SIRT6 were determined by RT-PCR using SYBR Green Mastermix (PCR Biosystem 
Ltd., London, UK). GAPDH served as an internal reference gene. The primer efficiencies are plotted in Sup-
plementary Fig. S1. RT-PCR was performed on CFX96 Real Time System (Bio-Rad Laboratories, Hercules, CA, 
USA).
Statistical analysis. All study groups involved in the analysis of SNP frequencies were tested for HWE. 
Chi-square or Fisher’s exact test was used to compare the genotype frequencies and allele distributions between 
cases and controls. Associations between genotypes and PD were estimated via odds ratio (OR) with 95% confi-
dence interval (CI). Genotype frequencies were compared between cases and controls under the additive, domi-
nant and recessive model.
The relative mRNA level was calculated by the  2−ΔΔCt  method42. For the identification of the outliers among 
 2−ΔΔCt replicates the ROUT method was implemented. D’Agostino and Pearson omnibus normality test was per-
formed for the analysis of data distribution. If the data showed Gaussian distribution, we implement unpaired 
t-test. In the case of non-Gaussian distribution Mann–Whitney U test was used for the comparison of the relative 
levels of mRNAs between different groups. Due to multiple comparisons FDR correction was implemented. A 
p value less than 0.05 was considered statistically significant. Statistical analyses were performed using PLINK, 
R and GraphPad Prism 6.0 softwares. LD and haplotype-based case–control analysis were performed with the 
use of Haploview 4.2 software.
Ethics approval and consent to participate. The study protocol was approved by the Medical Research 
Council Scientific and Research Ethics Committee (47066-3/2013/EKU (556/2013)) and Ethics Committee of 
the Faculty of Medicine (22/2012), University of Szeged. All study participants gave written informed consent in 
accordance with the Helsinki Declaration.
Data availability
The data used in the current study are available from the corresponding author on reasonable request.
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